Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

at we will conduct additional studies or that we will be successful in gaining regulatory approval of Cinryze for additional indications, formulations or in additional territories. There can be no assurance that: the FDA will confirm our belief that Vancocin meets the requirements for, and thus has received, three years of exclusivity, through listing an exclusivity code in the Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book), that even if FDA agrees that the label changes contained in our approved sNDA warrant exclusivity that the FDA would agree that omission of the protected labeling would render generic versions of Vancocin less safe and effective, the FDA will agree with the positions stated in ViroPharma's Vancocin-related submissions or that ViroPharma's efforts to oppose the FDA's bioequivalence recommendation for Vancocin through in vitro dissolution testing will be successful or that the courts reviewing the pending Vancocin related litigation will agree with our positions. In the event that the FDA does not grant three years of exclusivity in connection with the information updating our label through the approved sNDA, or decides that such protected labeling can be omitted from the label of a generic product, we cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If the FDA does not grant such three year exclusivity, or if exclusivity is granted and a generic manufacturer is nonetheless permitted to omit the protected data, and we are unable to change the FDA's bioequivalence recommendation for Vancocin, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancocin and our financial performance.  Biologics such as Cinryze require processing steps that are more difficult than those required for most chemical pharmaceuticals, and as a
'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2, 2015 GOJO, inventors of PURELL ® ... antibiotic stewardship at the White House Forum.  GOJO was ... organizations and stakeholders at the White House Forum to ... the emergence of antibiotic-resistant bacteria, detect resistant strains, preserve ... spread of resistant infections. "A primary prevention ...
(Date:6/2/2015)... 2, 2015 MGB Biopharma ... resistance problem  MGB Biopharma, a biopharmaceutical ... to address the major global problem of antibiotic ... stable intravenous (IV) formulation of MGB-BP-3, designed for the ... The intravenous formulation of MGB-BP-3 is ...
(Date:6/2/2015)... LA (PRWEB) June 02, 2015 ... gene synthesis to improve protein expression, announced the formation ... includes six executives and entrepreneurs with a broad range ... industries. , The team includes: , Jimmy Roussel, ... , Roussel has a background in technology and marketing. ...
(Date:6/1/2015)... 1, 2015  Turing Pharmaceuticals AG announced that life ... , MD, MSc,  has joined the company as ... Salinas, who holds a medical degree as well ... of significant accomplishments in the pharmaceutical industry, and ... Salinas has played a leadership role in numerous ...
Breaking Biology Technology:GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... Aug. 6 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs in ... today,announced that it will host a conference call ... on Thursday, August 14, 2008 at 10:00,a.m. (EDT). ...
... Aug. 6 Denham Capital,("Denham") announced today ... million in VitAG,Corporation ("VitAG"). VitAG technology converts ... capable of competing with and,outperforming conventional fertilizers. ... biosolids-to-fertilizer manufacturing plants., "Denham,s investment in ...
... the biometrics company enabling applications for the ... alliance with Methode Electronics, Inc. One of ... includes being a solid Tier 1 automotive ... subsystem devices. Together, Methode and Lumidigm will ...
Cached Biology Technology:Advanced Life Sciences To Host 2008 Second Quarter Financial Results Conference Call and Webcast 2Advanced Life Sciences To Host 2008 Second Quarter Financial Results Conference Call and Webcast 3Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids 2 Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development 2
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... University of Southampton and the Australian National University report that ... natural standards and at current rates may reach ... by 2200. The team used geological evidence of ... of natural sea-level rise. This was compared with historical tide-gauge ...
... have revealed the inner workings of the ozone hole ... chlorine in the stratosphere has not yet caused a ... years after the Montreal Protocol agreement limited human emissions ... the annual ozone hole and watched it essentially stabilize, ...
... 10, 2013 Spectrum Health will be the first ... in the nation to offer treatment with a newly ... for adult epilepsy patients whose seizures have not responded ... is an implantable therapeutic device designed to detect abnormal ...
Cached Biology News:What the past tells us about modern sea-level rise 2NASA reveals new results from inside the ozone hole 2NASA reveals new results from inside the ozone hole 3Spectrum Health to offer implantable neurostimulator for hard-to-treat epilepsy patients 2